Skip to main content

Advertisement

Table 4 Association between atopy and remission of respiratory symptoms classified by the treatment group and gender

From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study

Respiratory symptom Total population Males Females
  OR (95% CI) of phadiatop OR (95% CI) of phadiatop OR (95% CI) of phadiatop
  Placebo Budesonide Placebo Budesonide Placebo Budesonide
Wheezing at any time 0.99 (0.59–1.67) 1.18 (0.70–1.99) 0.88 (0.48–1.60) 1.26 (0.70–2.26) 2.06 (0.55–7.78) 0.51 (0.15–1.71)
Cough day/night or in a.m. 0.85 (0.53–1.36) 1.93 (1.11–3.37)*,$ 0.87 (0.52–1.45) 1.94 (1.05–3.57) * 0.79 (0.26–2.41) 1.84 (0.47–7.30)
Phlegm in day/night or in a.m. 1.21 (0.72–2.03) 1.67 (0.99–2.82)# 1.14 (0.65–2.00) 1.63 (0.93–2.87)# 1.48 (0.34–6.45) 1.53 (0.28–8.26)
Trouble with breathing 0.84 (0.48–1.47) 1.76 (0.99–3.11)# 0.96 (0.50–1.82) 2.76 (1.45–5.26) *,$ 0.47 (0.18–1.21) 0.43 (0.17–1.12)#
Woken with chest tightness 2.18 (0.97–4.90)# 2.32 (0.60–8.91) 2.17 (0.67–6.99) 1.33 (0.22–7.85) 5.76 (1.67–19.86) * 8.82 (0.63–123.66)
Attack of dyspnea after activity 1.01 (0.52–1.95) 1.11 (0.63–1.96) 1.04 (0.49–2.20) 0.87 (0.46–1.64) 1.03 (0.29–3.63) 3.67 (0.68–19.70)
  1. *OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarette and FEV1 % pred.
  2. #Trend (0.05 < p. value < 0.1). $Interaction between Phadiatop and treatment group has a p.value < 0.05.